Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction

被引：30

作者：

Kim, Young Hoon ^{[1
,4
]}

Choi, Hojin ^{[1
]}

Lee, Jaekwang ^{[1
]}

Hwang, In-Chang ^{[1
]}

Moon, Seung Kee ^{[1
]}

Kim, Soo Jin ^{[1
]}

Lee, Hong Woo ^{[1
]}

Im, Dai Sig ^{[1
]}

Lee, Sung Sook ^{[1
]}

Ahn, Soon Kil ^{[1
]}

Kim, Sang Woong ^{[2
]}

Han, Cheol Kyu ^{[3
]}

Yoon, Jeong Hyeok ^{[3
]}

Lee, Kyung Joo ^{[1
]}

Choi, Nam Song ^{[1
]}

机构：

[1] CKD Pharmaceut Inc, Chong Kun Dang Res Inst, Cheonan, South Korea

[2] LeadGenex, Venture Town Dasan, Taejon, South Korea

[3] Equispharm Inc, Gyeonggi Bioctr, Suwon 443766, Gyeonggi Do, South Korea

[4] Soong Sil Univ, Dept Chem, Seoul 156743, South Korea

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 23期

关键词：

PDE5; PDE6; PDE11; Inhibitor; Quinazoline; MED;

D O I：

10.1016/j.bmcl.2008.09.108

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In an effort to minimize side effects associated with low selectivity against PDE isozymes, we have successfully identified a series of 6,7,8-substituted quinzaolines as potent inhibitors of PDE5 with high level of isozyme selectivity, especially against PDE6 and PDE11. PDE5 potency and isozyme selectivity of quinazolines were greatly improved with substitutions both at 6- and 8-position. The synthesis, structure activity relationships and in vivo efficacy of this novel series of potent PDE5 inhibitors are described. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：6279 / 6282

页数：4

共 50 条

[21] Psychological Predictors of PDE5 Inhibitors in Vasculogenic Erectile Dysfunction
Palmas, Artur
Pascoal, Patricia
Nobre, Pedro
[J]. INTERNATIONAL JOURNAL OF SEXUAL HEALTH, 2019, 31 : A568 - A568
[22] PDE5 inhibitors: Is there more to come besides erectile dysfunction?
Stief, Christian
[J]. EUROPEAN UROLOGY, 2007, 52 (04) : 943 - 944
[23] PDE5 INHIBITORS FAILURES IN ERECTILE DYSFUNCTION - WHAT ARE THE CAUSES?
Fedorova, Anna
Vykhodtcev, Sergei
Lukyanov, Andrey
[J]. JOURNAL OF SEXUAL MEDICINE, 2017, 14 (05): : E306 - E306
[24] Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction
Dorsey, Philip
Keel, Christopher
Klavens, Meghan
Hellstrom, Wayne J. G.
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (07) : 1109 - 1122
[25] Highly potent and selective chiral inhibitors of PDE5: An illustration of Pfeiffer's rule
Bunnage, Mark E.
Mathias, John P.
Wood, Anthony
Miller, Duncan
Street, Stephen D. A.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (23) : 6033 - 6036
[26] An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction
Palit, Victor
Eardley, Ian
[J]. NATURE REVIEWS UROLOGY, 2010, 7 (11) : 603 - 609
[27] An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction
Victor Palit
Ian Eardley
[J]. Nature Reviews Urology, 2010, 7 : 603 - 609
[28] Combination of Vacuum Erection Device and PDE5 Inhibitors as Salvage Therapy in PDE5 Inhibitor Nonresponders with Erectile Dysfunction
Canguven, Onder
Bailen, James
Fredriksson, William
Bock, David
Burnett, Arthur L.
[J]. JOURNAL OF SEXUAL MEDICINE, 2009, 6 (09): : 2561 - 2567
[29] Practice pointer - Treating erectile dysfunction when PDE5 inhibitors fail
McMahon, CN
Smith, CJ
Shabsigh, R
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7541): : 589 - 592
[30] The impact of the use of PDE5 inhibitors for erectile dysfunction on the lives of Australian men
Matic, H.
McCabe, M. P.
[J]. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2007, 19 (04) : 418 - 423

← 1 2 3 4 5 →